For the first time in 14 years, France's National Health Authority (HAS) has issued a clear directive regarding autism treatment, stating that psychoanalysis is not recommended for autism spectrum disorder (ASD). This determination has sparked significant discussion and debate among families affected by autism, as well as among psychiatrists and psychologists in the country. The HAS, which is a key reference for health policies in France, emphasized that current evidence does not support the efficacy of psychoanalysis for treating ASD.

The HAS's new position is particularly noteworthy as it marks the first major document on autism released by the Authority since 2012, reflecting the evolving understanding of autism and its treatment. Families and healthcare professionals have been eagerly awaiting these updated guidelines in hopes of better addressing the complexities of autism. The recommendation is part of a broader effort to refine and improve therapeutic approaches for the estimated 1% to 2% of the population living with the disorder, who face challenges in social relationships and communication.

This shift may have significant implications for treatment approaches in France, potentially steering families and medical professionals towards evidence-based practices rather than psychoanalytic methods. The decision demonstrates a growing reliance on scientific evidence in health recommendations and may influence how the healthcare system supports those affected by autism moving forward. As discussions continue, the focus may shift towards integrating more modern therapies that are backed by research, ultimately aiming to provide better support and outcomes for individuals with autism.